Arbutus Biopharma(us:ABUS)
3.48
-0.29%
Updated on 2025-04-02
Open:3.46
Close:3.48
High:3.60
Low:3.41
Prev Close:3.49
Volume:1.36M
Turnover:4.77M
Turnover Ratio:0.71%
Shares:191.48M
MarketCap:666.35M
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 2 | 2526 | 0.00% | 0 | 1 | 0 |
| 2024-03-31 | 124 | 82950909 | 46.03% | 21 | 29 | 46 |
| 2023-12-31 | 113 | 78575172 | 46.26% | 19 | 34 | 35 |
| 2023-09-30 | 109 | 70948940 | 42.31% | 5 | 36 | 39 |
| 2023-06-30 | 127 | 66105606 | 39.60% | 11 | 38 | 53 |
| 2023-03-31 | 124 | 62040349 | 37.57% | 19 | 35 | 39 |
| 2022-12-31 | 134 | 54148212 | 34.39% | 11 | 47 | 54 |
| 2022-09-30 | 128 | 46535943 | 30.47% | 20 | 42 | 38 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-03-31 | Whitefort Capital Management, Lp | 12862152 | 7.14% | -334910 | -2.54% |
| 2024-03-31 | Blackrock Inc. | 10404619 | 5.77% | 14319 | 0.14% |
| 2024-03-31 | Morgan Stanley | 8830297 | 4.90% | 1846185 | 26.43% |
| 2024-03-31 | Two Seas Capital Lp | 7841927 | 4.35% | -1200000 | -13.27% |
| 2024-03-31 | Vanguard Group Inc | 5987907 | 3.32% | -976 | -0.02% |
| 2024-03-31 | Woodline Partners Lp | 4070659 | 2.26% | -649244 | -13.76% |
| 2024-03-31 | Hudson Bay Capital Management Lp | 3520382 | 1.95% | -619522 | -14.96% |
| 2024-03-31 | Fourworld Capital Management Llc | 3000527 | 1.67% | 1909676 | 175.06% |
| 2024-03-31 | Adage Capital Partners Gp, L.L.C. | 3000000 | 1.66% | 3000000 | |
| 2024-03-31 | Geode Capital Management, Llc | 2958887 | 1.64% | 141192 | 5.01% |
About
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
Address:701 Veterans Circle
Website:http://www.arbutusbio.com
Market Movers